【摘要】 目的探究脾氨肽口服冻干粉联合氯雷他定治疗儿童慢性荨麻疹临床疗效及预后。方法选取2016年3月至2017年3月本院诊治90例儿童慢性荨麻疹临床资料,分为2组,每组45例,对照组予以氯雷他定,研究组予以脾氨肽口服冻干粉联合氯雷他定,2组疗程均为1个月,分析2组患儿临床症状评分及血清IgE水平、不良反应、预后。结果研究组有效例数34例比对照组24例多,差异具统计意义(P<0.05);2组临床症状各项评分治疗后均较治疗前低,差异有统计学意义(P<0.05),且研究组治疗后风团数目(0.32±0.06)分、红晕直径(0.31±0.13)分、瘙痒(0.41±0.09)分显著优于对照组(P<0.05);研究组与对照组相比治疗前血清IgE水平差异无统计学意义(P>0.05),治疗2周和1个月后(70±10)U/mL和(57±10)U/mL显著更低(P<0.05);研究组不良反应总发生率11%与对照组13%相比差异无统计学意义(P>0.05);研究组治疗后6个月后复发率11%和对照组31%相比显著低,差异具有统计学意义(P<0.05)。结论与单用氯雷他定治疗比较,脾氨肽口服冻干粉联合氯雷他定治疗儿童慢性荨麻疹能显著改善其临床症状,且血清IgE水平明显降低,预后效果显著,具一定临床应用与研究价值。更多还原

【Abstract】 Objective To explore the clinical efficacy and prognosis of spleen aminopeptide oral lyophilized powder combined with loratadine for chronic urticaria in children.Methods The clinical data of 90 children with chronic urticaria who had received treatment in our hospital between March 2016 and March 2017 were selected and divided into 2 groups,with 45 cases in each group:the control group was given loratadine for treatment,whereas the observation group was treated with spleen aminopeptide oral lyophilized powder combined with loratadine.The treatment lasted for one month in both groups,and the clinical symptom score,serum IgE level,adverse reactions and prognosis effect in the two groups were analyzed.Results The number of cases with effective treatment in the study group was 34,larger than that in the control group,which was 24,and the difference was statistically significant(P<0.05).The scores of clinical symptoms in both groups after treatment were shown to be lower than before treatment,with statistically significant difference(P<0.05),and the scores on the number of wheals,blush diameter and pruritus in the study group were(0.32±0.06),(0.31±0.13)and(0.41±0.09),respectively,all shown to be significantly better than those of the control group(P<0.05).The comparison of serum IgE level between the two groups showed no significant difference before treatment(P>0.05),but significantly reduced 2 weeks and 1 month after treatment,when the level was(70±10)U/mL and(57±10)U/mL(P<0.05),respectively.The total incidence of adverse reactions showed no significant difference between the two groups(P>0.05);180 drecurrence in the study group was 11%,shown to be significantly lower than that in the control group,which was 31%,and the difference was statistically significant(P<0.05).Conclusion Compared with loratadine only,spleen aminopeptide oral lyophilized powder combined with loratadine can significantly improve the clinical symptoms of children with chronic urticaria,reduce the level of serum IgE,and produce significant prognosis effect;therefore,it is of certain value in clinical application and research.更多还原